The AI-driven nanomaterial innovator Insilico Medicine (7666.HK) has initiated its Hong Kong IPO and is set to commence trading on May 13. With an expected market capitalization of approximately HKD 12.1 billion, the company will become the third 'AI + Pharma' firm to list in Hong Kong, following XtalPi and Insilico Medicine, drawing significant market attention. As a leading innovator in the AI drug development sector, the company is entering the Hong Kong market with its globally advanced AI drug discovery platform and a robust list of cornerstone investors. However, its pre-commercialization stage, highly uncertain revenue streams, and the unpredictable pace of industry growth in the near term collectively indicate that this will be a value marathon testing investors' long-term vision and patience.
The lineup of cornerstone investors for this IPO is notably strong, representing a key highlight of the offering. These cornerstone investors have collectively subscribed to approximately 54.9% of the shares. For an AI pharmaceutical company with high technical barriers still in its early commercial phase, this offering structure, largely secured by professional institutions, is reasonable—it places most of the allocation with entities that have deeper industry understanding and higher risk tolerance, offering a layer of protection for retail investors.
Leading the cornerstone investment is the global top asset management firm BlackRock, with a commitment of USD 50 million, accounting for 33.8% of the total cornerstone investment, serving as a stabilizing anchor. Besides BlackRock, the cornerstone list includes several globally renowned specialized funds in the healthcare and pharmaceutical sectors, with investment entities spanning major capital markets such as the UK, the US, and Japan, reflecting a preliminary consensus among global capital on Insilico Medicine's technological approach and long-term value.
As a core enterprise in China's 'AI + Pharma' sector, Insilico Medicine, along with XtalPi and another AI drug developer, are collectively referred to as the industry's 'three dragons.' The other two companies have already completed their Hong Kong listings and have garnered substantial market attention post-IPO, with their share prices achieving significant gains, fully demonstrating the capital market's long-term optimism towards the AI drug development track.
XtalPi listed at HKD 24.1 per share, with its post-listing price peaking at HKD 80.9, nearly a fourfold increase, and is currently trading around HKD 64.3, still representing an approximate 2.7-fold gain from the IPO price. The other listed peer had an IPO price of HKD 5.3; its share price experienced considerable volatility—reaching a high of HKD 16.2 in September 2024, declining to HKD 3.05 in December of the same year, and recovering to HKD 15.12 by October 2025, with the latest price around HKD 9 per share, still nearly double its IPO price.
In terms of market capitalization, Insilico Medicine's IPO implies a market cap of about HKD 12.1 billion, significantly lower than the current market caps of its two listed peers—approximately HKD 38.7 billion and HKD 36.8 billion, respectively. Some market observers believe Insilico Medicine has potential room to converge towards the valuation levels of these leading firms post-listing.
Given the company's currently singular revenue structure, a price-to-sales (P/S) ratio comparison offers limited reference value. In 2025, the company generated revenue of RMB 105 million, primarily from the upfront payment for the out-licensing of its pipeline product MTS-004. The scale and timeline of future commercial revenue remain highly uncertain.
In contrast, the market capitalization-to-R&D expenditure ratio may be a more comparable valuation metric. Data shows Insilico Medicine's R&D expenditure in 2025 was RMB 270 million, implying a market cap-to-R&D ratio of approximately 40 times. The same ratio for its two listed peers is around 60 times. From this core metric perspective, Insilico Medicine's current valuation shows relative advantages and potential upside.
Insilico Medicine's financial data clearly delineates its critical transition from a research platform towards commercialization. From 2023 to 2025, the company's revenues were RMB 9.34 million, RMB 1.48 million, and RMB 105 million, respectively. The explosive growth in 2025, a 6985% year-on-year increase, was due to the recognition of the upfront payment from the out-licensing of MTS-004. The gross profit margin also surged from 55.5% in 2024 to 98.2% in 2025, showcasing the high-profit characteristics of the technology licensing model.
However, the company remains in a loss-making phase. Net losses from 2023 to 2025 were RMB 582 million, RMB 499 million, and RMB 392 million, respectively, showing a year-on-year narrowing trend but remaining substantial in absolute terms. Excluding the impact of non-cash items such as share-based compensation and fair value changes of convertible loans, the adjusted net loss narrowed from RMB 347 million in 2023 to RMB 180 million in 2025, indicating a significant improving trend.
The company's core expenditure lies in R&D, with investments of RMB 290 million, RMB 274 million, and RMB 270 million from 2023 to 2025, remaining relatively stable. As of the end of 2025, the company held cash and equivalents of RMB 828 million. Combined with the IPO proceeds, management estimates financial viability for approximately 133 months, indicating ample funding reserves.
Nevertheless, it is crucial to recognize that the stability of current revenue has not yet been established. The 2025 revenue primarily stemmed from the recognition of a RMB 100 million upfront payment for MTS-004's out-licensing. Although the company anticipates multiple potential collaborations and out-licensing deals within 24 months post-listing, its ability to generate revenue remains difficult to predict accurately until these transactions are finalized.
The nanomedicine field where Insilico Medicine operates is a sector with high long-term certainty but requires patience. According to a Frost & Sullivan report, the global nanomedicine market is projected to grow from USD 222 billion in 2024 to USD 585.4 billion by 2035, representing a compound annual growth rate (CAGR) of 9.2%. Within the AI drug development segment specifically, global AI-enabled pharmaceutical R&D expenditure is expected to reach USD 123.9 billion by 2035, with a CAGR of 22.2% from 2024 to 2035.
Insilico Medicine has established significant technological barriers. It possesses the industry's first and largest lipid library (over 10 million structures) and the world's sole AI platform capable of predicting lipid and LNP properties. In its clinical pipeline, the company has four preclinical candidate drugs, three clinical-stage pipeline products, and one product in the Pre-NDA stage.
However, the industry remains in its early stages. In the foreseeable future, the nanomedicine market is unlikely to enter a phase of explosive growth, suggesting Insilico Medicine may require a longer timeframe to validate the sustainability of its business model. The competitive landscape the company faces is equally noteworthy—it includes not only AI pharmaceutical peers like XtalPi and others but also international AI drug development firms such as Alnylam and Moderna. In this arena, the contest of technology and capital will be a protracted marathon.